France,Switzerland,United Kingdom,United States : ISIS PHARMACEUTICALS gets $1 million milestone payment from GLAXOKLINESMITH.
Isis Pharmaceuticals, Inc. earned $1 million milestone payment from GlaxoSmithKline pertaining to the advancement of ISIS-TTR in a randomized, double-blind, placebo-controlled phase II/III study in patients suffering from familial amyloid polyneuropathy (FAP).
The study evaluates the effects of ISIS-TTR on neurological dysfunction and the quality of life of the patients. Results support the filing of a marketing approval application of ISIS-TTR for the indication.
Isis Pharma inked a deal with Glaxo in March 2010 for the development of up to 6 programs. The companies are working on 5 active programs, which include ISIS-TTR.
Isis Pharma will receive total milestone payments of $50 million from Glaxo for the development of ISIS-TTR. The payment of $1 million marks the 4th installment. To date, Isis Pharma has received $26 million, including upfront and milestone payments.
Glaxo has an option to exclusively license ISIS-TTR. Isis Pharma will receive license and regulatory fees, sales milestone payments and double-digit royalties on ISIS-TTR net sales, if Glaxo exercises this option.
Isis Pharma and Glaxo are conducting an open-label extension study on ISIS-TTR in FAP patients who have completed dosing in the phase II/III study.
Isis Pharma has partnership agreements with leading pharmaceuticals companies like Biogen Idec and Roche among others.
Isis Pharma earned a milestone payment of $14 million from Biogen to initiate a phase I study on ISIS-DMPK for the treatment of myotonic dystrophy type I.
2014 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 28, 2014|
|Previous Article:||Ethiopia,Norway : NORWAY makes 60mln dollar financial support for building green economy in ETHIOPIA.|
|Next Article:||United Kingdom : EE decides to switch on 4G mobile broadband in NEWTON ABBOT.|